Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2021-12-07 Director's Dealing
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document explicitly uses the header "Directors’ Dealings" and the regulatory disclosure title "Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details a transaction (Acquisition) by an individual named Oliver R. Baumann, who is a Member of the managing body, including the date, price, volume, and stock identifier (ISIN). This content directly matches the definition for Director's Dealing.
2021-12-07 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the person (Oliver R. Baumann), their position ('Member of the managing body'), the nature of the transaction ('Acquisition'), the price, volume, and date of the transaction. This content directly matches the definition for Director's Dealing.
2021-12-03 English
New Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is explicitly titled a 'DGAP Press release' and 'Media release' announcing that 'Xlife Sciences appoints new Chief Financial Officer'. This concerns a change in senior management personnel. This directly matches the definition for Board/Management Information (MANG). Although it is distributed via RNS/DGAP channels, the core content is management change, not a general regulatory filing (RNS) or a report publication announcement (RPA). The length (5437 chars) is substantial enough to be the primary announcement, not just a pointer to a report.
2021-12-01 English
Xlife Sciences AG appoints new Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is explicitly titled 'DGAP Press release' and 'Media release'. It announces a specific corporate event: the appointment of a new Chief Financial Officer (CFO). This type of announcement, detailing changes in senior management, directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). Given the content focuses entirely on personnel change at the executive level, MANG is the most appropriate classification.
2021-12-01 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'DGAP-DD: Xlife Sciences AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. Section 4 details the 'transaction(s)', including the nature ('Acquisition'), price, volume, and date. This content directly matches the definition for Director's Dealing (Code: DIRS). The document length is short (2172 chars), but the content is the primary disclosure itself, not an announcement of a separate report.
2021-11-29 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the person (Oliver R. Baumann), their position (Member of the managing body), the nature of the transaction (Acquisition), the financial instrument (Share), and the date and price of the transaction. This content directly matches the definition for Director's Dealing (DIRS). The document length is short, but the content is the primary disclosure itself, not an announcement of a report.
2021-11-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.